Suggested remit: To appraise the clinical and cost effectiveness of mosunetuzumab within its marketing authorisation for treating relapsed or refractory follicular lymphoma.
 
Status In progress
Technology type Medicine
Decision Selected
Process STA 2022
ID number 3931

Provisional Schedule

Committee meeting: 1 01 November 2022
Expected publication 25 January 2023

Project Team

Project lead Louise Jafferally

Email enquiries

Stakeholders

Companies sponsors Roche (mosunetuzumab)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Blood Cancer UK
  Leukaemia Care
  Lymphoma Action
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists
Associated public health groups None
Comparator companies Bristol Myers Squibb (lenalidomide) (confidentiality agreement signed, participating)
  Accord Healthcare (bendamustine) (confidentiality agreement not signed, not participating)
  Dr Reddy’s Laboratories (bendamustine) (confidentiality agreement not signed, not participating)
  Napp Pharmaceuticals (rituximab) (confidentiality agreement not signed, not participating)
  Pfizer (rituximab) (confidentiality agreement not signed, not participating)
  Roche (obinutuzumab, rituximab) (confidentiality agreement not signed, not participating)
  Sandoz (rituximab) (confidentiality agreement not signed, not participating)
  Seacross Pharmaceuticals (bendamustine) (confidentiality agreement not signed, not participating)
  Zentiva (bendamustine) (confidentiality agreement not signed, not participating)
General commentators All Wales Therapeutics & Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
03 March 2022 In progress. ITP issued
03 March 2022 Invitation to participate
08 December 2021 - 14 January 2022 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual